Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Atria Investments Inc

Atria Investments Inc trimmed its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 7.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,981 shares of the company’s stock after selling 452 shares during the quarter. Atria Investments Inc’s holdings in Moderna were worth $400,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in MRNA. Ashton Thomas Private Wealth LLC purchased a new stake in Moderna in the 2nd quarter valued at $26,000. Family Firm Inc. purchased a new position in shares of Moderna during the 2nd quarter worth $33,000. Bank & Trust Co purchased a new position in shares of Moderna during the 2nd quarter worth $36,000. Hanseatic Management Services Inc. purchased a new position in shares of Moderna during the 2nd quarter worth $48,000. Finally, Plato Investment Management Ltd grew its holdings in shares of Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after purchasing an additional 288 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Trading Up 4.0 %

NASDAQ:MRNA opened at $38.40 on Friday. The company has a market cap of $14.78 billion, a PE ratio of -6.35 and a beta of 1.69. Moderna, Inc. has a 52 week low of $35.80 and a 52 week high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average is $56.13 and its two-hundred day moving average is $95.05.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business’s revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the business posted ($1.39) EPS. On average, analysts predict that Moderna, Inc. will post -9.44 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MRNA. Leerink Partners decreased their target price on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. TD Cowen reduced their price target on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and cut their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Bank of America cut their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research report on Friday, September 13th. Finally, Wolfe Research assumed coverage on Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $84.00.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 13.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 2,930 shares of company stock valued at $217,170 in the last quarter. Corporate insiders own 15.70% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.